Pathstone Holdings
DNA icon

Pathstone Holdings’s Ginkgo Bioworks DNA Stock Holding History

Pathstone Holdings’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,562
Closed -$20.9K – 2349
2024
Q2 		$20.9K Buy
1,562
+232
+17% +$6.92K ﹤0.01% 2288
2024
Q1 		$61.7K Sell
1,330
-308
-19% -$15.9K ﹤0.01% 2246
2023
Q4 		$111K Buy
+1,638
New +$100K ﹤0.01% 2137

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pathstone Holdings's DNA Position: Q3 2024 in Review

Pathstone Holdings sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 1,562 shares — an estimated $20.9K sold.

Pathstone Holdings first reported a position in DNA in Q4 2023 and held it in 3 quarters. The position peaked at $111K in Q4 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Pathstone Holdings reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Pathstone Holdings sold 1,562 Ginkgo Bioworks shares in Q3 2024, an estimated $20.9K.
  • Pathstone Holdings first reported a position in Ginkgo Bioworks in Q4 2023 and held it in 3 quarters.
  • Pathstone Holdings's Ginkgo Bioworks position peaked at $111K in Q4 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Pathstone Holdings's 13F filing for Q3 2024, filed 7 Nov 2024.